by Samsara@8529 | Jun 21, 2023 | Home, News
News Article Samsara Therapeutics adds eminent neurologist Professor Dame Pamela Shaw to its scientific advisory board to help accelerate ALS/MND treatment development 14th June 2023. Samsara Therapeutics, the autophagy biotech company, has appointed eminent... by Samsara@8529 | May 24, 2023 | Home, News
News Article Samsara Therapeutics Parkinson’s drug receives funding boost from The Michael J. Fox Foundation Monday 22nd May 2023. Samsara Therapeutics, a biotech committed to harnessing autophagy to prevent disease and increase health span, announced today... by Samsara@8529 | Apr 27, 2023 | Home, News
News Article Samsara Therapeutics unveils promising autophagy drug candidate, offering new hope for people with Parkinson’s and motor neurone disease Wednesday 26th April 2023. Today’s announcement from Chief Scientific Officer, Peter Hamley, puts Samsara... by Samsara@8529 | Oct 13, 2022 | Home, News
News Article CMT Research Foundation and Samsara Therapeutics Partner on a Novel Therapeutic Approach for CMT1A with the Potential to Reach Clinical Trials ATLANTA, GA and OXFORD, UK (October 13, 2022) The CMT Research Foundation (CMTRF), a non-profit focused... by Samsara@8529 | Jan 5, 2022 | Home, News
News Article Samsara Therapeutics Establishes Scientific Advisory Board Michael Schlossmacher, Susan Perlman, Ed Tate and Christian Behl to help advance development of neurodegeneration and rare genetic disease therapeutics Oxford, UK and Boston, US, 06 January... by Samsara@8529 | Dec 29, 2021 | Home, News
Insights / News Article More additions to the Samsara Therapeutics team Dec 01, 2021 We’re pleased to report that we’ve further strengthened our team in Oxford. Matthew Williamson is an expert in stem cells and patient-derived assays for Parkinson’s Disease, an...